Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 28.85 USD 1.41% Market Closed
Updated: Aug 14, 2024
Have any thoughts about
Pfizer Inc?
Write Note
Section:
 

Wall Street
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 33.2 USD with a low forecast of 27.27 USD and a high forecast of 47.25 USD.

PFE Lowest Forecast
Wall Street Target
27.27 USD
5% Downside
PFE Average Forecast
Wall Street Target
33.2 USD
15% Upside
PFE Highest Forecast
Wall Street Target
47.25 USD
64% Upside
Lowest
Price Target
27.27 USD
5% Downside
Average
Price Target
33.2 USD
15% Upside
Highest
Price Target
47.25 USD
64% Upside

PFE Last Price Targets
Pfizer Inc

The latest public price target was made on Aug 7, 2024 by Narumi Nakagiri from Daiwa , who expects PFE stock to rise by 18% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Narumi Nakagiri
Daiwa
34 USD
Upside 18%
1 week ago
Aug 7, 2024
Daiwa Securities Upgrades Pfizer (PFE) to Outperform (2)
StreetInsider
Mohit Bansal
Wells Fargo
30 USD
Upside 4%
2 weeks ago
Jul 31, 2024
Pfizer price target raised to $30 from $28 at Wells Fargo
TheFly
Chris Shibutani
Goldman Sachs
34 USD
Upside 18%
2 weeks ago
Jul 31, 2024
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
StreetInsider
Vamil Divan
Guggenheim
36 USD
Upside 25%
2 weeks ago
Jul 30, 2024
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga
Carter Gould
Barclays
30 USD
Upside 4%
1 month ago
Jul 10, 2024
Pfizer price target raised to $30 from $28 at Barclays
TheFly
Evan Seigerman
BMO Capital
36 USD
Upside 25%
2 months ago
May 22, 2024
Pfizer cost reduction program a positive for the shares, says BMO
TheFly
Louise Chen
Cantor Fitzgerald
45 USD
Upside 56%
6 months ago
Feb 14, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Thomas Yeh
Morgan Stanley
20 USD
Downside 31%
8 months ago
Dec 14, 2023
Harmonic To Rally Over 80%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Terence Flynn
Morgan Stanley
37 USD
Upside 28%
8 months ago
Nov 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Unknown Analyst
Morgan Stanley
45 USD
Upside 56%
1 year ago
Feb 1, 2023
Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $45
Benzinga
Unknown Analyst
Barclays
44 USD
Upside 53%
1 year ago
Feb 1, 2023
Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $44
Benzinga
Unknown Analyst
Credit Suisse
50 USD
Upside 73%
1 year ago
Feb 1, 2023
Credit Suisse Maintains Outperform on Pfizer, Lowers Price Target to $50
Benzinga
Unknown Analyst
Leerink Partners
48 USD
Upside 66%
1 year ago
Feb 1, 2023
SVB Leerink Maintains Market Perform on Pfizer, Lowers Price Target to $48
Benzinga
Unknown Analyst
Atlantic Equities
46 USD
Upside 59%
1 year ago
Feb 1, 2023
Atlantic Equities Maintains Neutral on Pfizer, Lowers Price Target to $46
Benzinga
Show More Price Targets
Show Less Price Targets
Narumi Nakagiri
Daiwa
Price Target 34 USD
Upside/Downside 18%
View Source
Mohit Bansal
Wells Fargo
Price Target 30 USD
Upside/Downside 4%
View Source
Chris Shibutani
Goldman Sachs
Price Target 34 USD
Upside/Downside 18%
View Source
Vamil Divan
Guggenheim
Price Target 36 USD
Upside/Downside 25%
View Source
Carter Gould
Barclays
Price Target 30 USD
Upside/Downside 4%
View Source
Evan Seigerman
BMO Capital
Price Target 36 USD
Upside/Downside 25%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 45 USD
Upside/Downside 56%
View Source
Thomas Yeh
Morgan Stanley
Price Target 20 USD
Upside/Downside 31%
View Source
Terence Flynn
Morgan Stanley
Price Target 37 USD
Upside/Downside 28%
View Source
Unknown Analyst
Morgan Stanley
Price Target 45 USD
Upside/Downside 56%
View Source
Unknown Analyst
Barclays
Price Target 44 USD
Upside/Downside 53%
View Source
Unknown Analyst
Credit Suisse
Price Target 50 USD
Upside/Downside 73%
View Source
Unknown Analyst
Leerink Partners
Price Target 48 USD
Upside/Downside 66%
View Source
Unknown Analyst
Atlantic Equities
Price Target 46 USD
Upside/Downside 59%
View Source
Show More Price Targets
Show Less Price Targets
Pfizer Inc Competitors:
Price Targets
O
OGI
OrganiGram Holdings Inc
54% Upside
GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
2% Downside
FUM
Futura Medical PLC
279% Upside
VY4
SNDL Inc
91% Upside
O
OGI
OrganiGram Holdings Inc
54% Upside
GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
2% Downside
FUM
Futura Medical PLC
279% Upside
VY4
SNDL Inc
91% Upside
SAN
Sanofi SA
15% Upside
SUPRIYA
Supriya Lifescience Ltd
8% Downside
VRCA
Verrica Pharmaceuticals Inc
200% Upside
C
300765
CSPC Innovation Pharmaceutical Co Ltd
68% Upside

Revenue
Forecast

Revenue Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 3 years is 3%.

2%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 3 years is 17%.

-1%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-22%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 3 years is 99%.

-14%
Past Growth
99%
Estimated Growth
Estimates Accuracy
-35%
Average Miss
What are analyst estimates?

See Also

Summary
PFE intrinsic value, competitors valuation, and company profile.
DCF Valuation
PFE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PFE stock valuation using valuation multiples.
Wall Street Estimates
PFE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PFE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PFE's stock price target?
Price Target
33.2 USD

According to Wall Street analysts, the average 1-year price target for PFE is 33.2 USD with a low forecast of 27.27 USD and a high forecast of 47.25 USD.

What is Pfizer Inc's Revenue forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 3 years is 3%.

What is Pfizer Inc's Operating Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 3 years is 17%.

What is Pfizer Inc's Net Income forecast?
Projected CAGR
99%

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 3 years is 99%.

Back to Top
ALPHA SPREAD
Join more than 166,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.